ArticleResearch square2026
Alzheimer's Disease Neuropathological characterization of the dog brain and relationship to biofluid biomarkers and cognitive function.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder and a major global health challenge affecting more than 55 million people worldwide. AD is clinically defined by progressive cognitive decline and neuropathologically characterized by the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs). While transgenic rodent models have provided valuable mechanistic insights, they do not fully capture the spontaneous, age-related nature of human AD. In contrast, the companion dog develops naturally occurring age-associated cognitive decline and AD-like neuropathological features, including Aβ deposition and tau pathology, and behavioral impairments measurable by the validated cognitive scales, Canine Cognitive Dysfunction Rating (CCDR). However, the systematic application of human AD neuropathological criteria to canine brains has been limited. Objective: The objective of this study was to apply established human neuropathological criteria (Thal, Braak, and CERAD) to aged canine brains and examine relationships among neuropathology, cognitive status, and plasma biomarkers. Methods: Postmortem brain tissues from 24 client-owned senior dogs were evaluated using Thal phases for Aβ deposition, Braak-based regional assessment of tau pathology, and CERAD criteria for neuritic plaques. Neuropathological findings were integrated with antemortem owner-reported cognitive assessments and plasma biomarker measurements to evaluate the clinico-pathologic and biomarker associations. Results: Senior dogs exhibited Aβ deposition consistent with early to intermediate Thal phases, variable and regionally restricted tau pathology, and an absence of neuritic plaques. Quantitative analysis demonstrated greater Aβ burden in cognitively impaired dogs compared with cognitively intact dogs, while age, but not cognitive score, was strongly associated with regional Aβ burden. Further, plasma glial fibrillary acidic protein (GFAP) levels showed a significant positive correlation with Aβ plaque burden, whereas the other plasma biomarkers assessed did not. Conclusion: Senior dogs exhibit neuropathologic features consistent with early-stage AD-like pathology, characterized by Aβ deposition and limited tau pathology in the absence of neuritic plaques. These findings support the utility of the companion dog as a naturally aging model for investigating early ADrelated pathological processes and evaluating translational biomarkers during preclinical disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.